The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2018Studying GBA Pseudogene as a Controller of GBA and Alpha-synuclein
Study Rationale:
Mutations (changes) in the GBA gene are the most common genetic risk factor for Parkinson’s disease (PD). GBA has a clone called pseudogene, a similar stretch of DNA that, unlike the... -
GBA Biology and Therapies, 2018Link between LRRK2 Activity and Glucocerebrosidase Deficits in Idiopathic Parkinson’s Disease
Study Rationale:
Earlier work from this group reported greater LRRK2 activity in people with idiopathic (cause unknown) Parkinson’s. This project builds on those findings to investigate how that... -
GBA Biology and Therapies, 2018Analyzing Genetic Modifiers Using a CRISPR Activation/Inhibition GBA-PD Model
Study Rationale:
Clinical and genetic studies show that mutations in the GBA gene are risk factors for developing Parkinson’s disease (PD) and lead to an accumulation of glycolipids in the lysosome... -
GBA Biology and Therapies, 2018Targeting GCase with Novel Pharmacological Chaperones
Study Rationale:
People who have mutations in the GBA gene have a higher chance of developing Parkinson's disease (PD). The GBA gene encodes the glucerebrosidase (GCase) protein, an enzyme located... -
GBA Biology and Therapies, 2018Impact of Genetic Variants in GBA on Parkinson’s Disease
Study Rationale:
Changes to the DNA sequence are risk factors for Parkinson’s disease. While we know where many of these changes occur in our DNA, we still do not know how they cause Parkinson’s... -
GBA Biology and Therapies, 2018Genotypic Influences on Network Progression in Parkinson’s Disease
Study Rationale:
Parkinson’s disease patients with mutations in the glucocerebrosidase (GBA) gene tend to have a more aggressive disease course. GBA pathways may therefore constitute a discrete target...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.